Top Executive Sells Massive Shares in Nuvation Bio!

Tip Ranks
2025.12.04 02:05

Nuvation Bio's CMO, Liu Dongfang, sold 150,000 shares for $1,173,000. The company discontinued its NUV-1511 program due to inconsistent efficacy, focusing on other pipeline molecules. Despite this, analysts remain positive, highlighting promising Phase 2 results for safusidenib. Spark rates NUVB as Neutral, citing weak financials and speculative nature. The stock has a YTD price performance of 188.42% and a market cap of $2.57B.

New insider activity at Nuvation Bio ( (NUVB) ) has taken place on December 3, 2025.

TipRanks Cyber Monday Sale

  • Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

CMO Liu Dongfang recently sold 150,000 shares of Nuvation Bio stock, amounting to a total transaction value of $1,173,000.

Recent Updates on NUVB stock

Nuvation Bio recently announced the discontinuation of its NUV-1511 program due to inconsistent efficacy, redirecting resources to other pipeline molecules and next-generation DDC candidates. Despite this, analysts have maintained a positive outlook, citing the potential of other assets like safusidenib and taletrectinib. The publication of promising Phase 2 study results for safusidenib in IDH1-mutant gliomas has bolstered confidence, with the study meeting its primary endpoint and showing a high progression-free survival rate at 24 months. Analysts have raised price targets based on these developments, emphasizing the long-term potential of Nuvation Bio’s pipeline.

Spark’s Take on NUVB Stock

According to Spark, TipRanks’ AI Analyst, NUVB is a Neutral.

Nuvation Bio’s stock is primarily challenged by weak financial performance, characterized by ongoing losses and negative cash flows, despite a strong equity foundation. While there is short-term momentum in the stock price, the lack of sustainable income and negative valuation metrics, such as a negative P/E ratio, weigh heavily on the overall score. The stock’s speculative nature and reliance on future growth prospects contribute to its moderate overall score.

To see Spark’s full report on NUVB stock, click here.

More about Nuvation Bio

YTD Price Performance: 188.42%

Average Trading Volume: 9,038,979

Technical Sentiment Signal: Buy

Current Market Cap: $2.57B

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.